ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
77.57
0.17
(0.22%)
Closed March 18 04:00PM
77.45
-0.12
(-0.15%)
After Hours: 07:26PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

CVS News

Official News Only

CVS Discussion

View Posts
3antar 3antar 1 month ago
Looking great so far.. let's go
👍️0
DiscoverGold DiscoverGold 1 month ago
$CVS higher in pre-market following a double earnings beat
By: TrendSpider | February 7, 2024

• $CVS higher in pre-market following a double earnings beat.

~EPS: $2.12 vs $1.99 est
~SALES: $93.81B vs $90.36B est

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 2 months ago
Is the Worst Over for CVS Health Stock?
By: Schaeffer's Investment Research | January 29, 2024

• The security could bounce off the 80-day trendline

• CVS shed more than 16% in the last 12 months

CVS Health Corp (NYSE:CVS) stock was last seen up 0.6% at $73.40, extending a bounce off the $70 level. While the security carries a 16.9% year-over-year deficit and last week fell under its 50-day moving average for the first time since December, there's indication this underperformance could soon be a thing of the past. CVS Health stock's most recent pullback placed it within a trendline with historically bullish implications.

Specifically, CVS is within one standard deviation of its 80-day trendline. Per data from Schaeffer's Senior Quantitative Analyst Rocky White, the security saw no fewer than five similar signals in the last three years, defined for this study as having traded north of this moving average 80% of the time during the last two months, and in eight of the past 10 trading days.



CVS was higher one month later in 80% of those instances, with an average 3.9% gain. A move of similar magnitude from its current perch would place the security back above $76.

Over at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the security's 10-day call/put volume ratio sits in the 80th percentile of its annual range. This means an unwinding of pessimism could boost CVS.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 2 months ago
Healthcare Stocks Slide After Humana Forecast
By: Schaeffer's Investment Research | January 18, 2024

• Humana's disappointing 2023 profit outlook is weighing on healthcare sector

• Humana stock is trading at two-year lows after the report

The healthcare sector is taking a hit after Humana Inc (NYSE:HUM) today slashed its 2023 profit outlook, citing higher-than-anticipated medical costs in the fourth quarter. UnitedHealth Group Inc (NYSE:UNH) and CVS Health Corp (NYSE:CVS) are two notable names falling after the report, as both extend an already rocky start to 2024.

At last glance, Humana stock is trading at two-year lows, down 10.9% at $398.84 -- earlier as low as $390.50 -- and on the short sell restricted (SSR) list. Since last January, HUM is down 17.5%. So far in the options pits, 20,000 calls and 23,000 puts have been exchanged, which is already 4.2 times the average daily volume. The January 2026 400-strike put is the most popular, where new positions are being opened.

Meanwhile, UnitedHealth Group stock was last seen down 2.8% at $510.04, hitting $497.96 at its lowest level today. Sinking below its 140-day moving average, which previously caught a pullback this month, the equity is currently grappling with its 200- and 320-day trendlines. Since last January, the security is up 7.1%. In the options pits, UNH is seeing three times the volume typically seen at this point, with the most activity at the January 500 put.

The shares of CVS Health stock were last seen down 4.6% at $73.42, though potential support lingers just below at the 80-day moving average, as well as former pressure at the $72 region. Today's drop has the stock on track for its seventh daily loss in the last eight sessions. Year-over-year, the equity is down 16.7%. Options traders are targeting CVS at triple the usual intraday volume as well, with new positions being opened at the most active contract, the January 70 put.

Read Full Story »»»

DiscoverGold
👍️0
3antar 3antar 3 months ago
I like the buy rating and the $94 price target set by HSBC.
👍️0
krobar krobar 3 months ago
After the stock has rallied 10 points
👍️0
DiscoverGold DiscoverGold 3 months ago
CVS sell-off overdone says HSBC, Walgreens Boots Alliance 'execution risks are significant'
By: Investing | December 22, 2023

HSBC initiated CVS Health (NYSE:CVS) with a Buy rating and Walgreens Boots Alliance (NASDAQ:WBA) with a Hold rating in a note to clients Friday, stating healthcare business models have been in constant flux.

While the market is still quite fragmented, HSBC believes there are attractive growth opportunities.

CVS was assigned a $94 per share price target, implying a potential 21.7% upside from current levels. The bank said the company has an attractive and undervalued moat and is trading at a steep discount to historical levels.

In addition, HSBC said that with the company's shares "down roughly 18% LTM (vs SPX up by 23% over the same period)," the sell-off "appears overdone."

WBA was assigned a $27 per share price target. HSBC believes the company requires operational discipline to improve its execution, boost overall performance, and restore profitability.

Furthermore, while WBA faces "near-term operational challenges," it could unlock value, but the "execution risks are significant," according to analysts.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 3 months ago
Earnings expectations now reset for CVS says BofA as stock rally extends
By: Investing | December 6, 2023

CVS Health (NYSE:CVS) stock has continued to rally on Wednesday, extending a two-day rally to as much as 8.6%.

The surge follows the pharmacy chain's positive 2024 revenue guidance and the introduction of a new reimbursement model aimed at simplifying drug pricing.

Walgreens Boots (NASDAQ:WBA), a peer in the industry, also saw an increase of up to 4.2%.

Analysts at Bank of America view CVS's adjusted earnings growth expectations as appropriately reset for the intermediate term and believe the new reimbursement model could have a significant impact on the prescription ecosystem.

The firm maintains a Buy rating with a price target of $86.

“Overall, CVS has a differentiated brand versus other health plans (given the retail/consumer footprint) which uniquely positions CVS to engage with members across the continuum. CVS’ introduction of a new CVS Health app that integrates an entire member’s experience into one smartphone application creates optionality for synergies between operating segments and we expect the company to speak about this more over time.”

“Further, CVS’ segment level detail provided us with increased confidence the company can execute against and outperform mid-to-high single digit EPS growth targets.”

CVS's year-to-date decline now stands at 21%.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 3 months ago
CVS Health adds 2% as 2024 revenue outlook tops estimates
By: Investing | December 5, 2023

CVS Health (NYSE:CVS) has forecasted revenue for 2024 to be at least $366 billion, which exceeds the current Street estimate of $345.5 billion.

The company anticipates adjusted earnings per share of at least $8.50, in line with the consensus, with the cash flow from operations projected to be at least $12.5 billion. Updates were shared ahead of the company’s 2023 Investor Day.

CVS shares rose 2.2% on the news.

CVS Health also said it plans to introduce a new pharmacy reimbursement model called CVS CostVantage, aimed at evolving the traditional reimbursement model and providing greater transparency and simplicity.

"We are leading with an approach that will shift how our retail pharmacy is compensated by implementing a more transparent and sustainable model that fairly aligns pharmacy reimbursement to the quality services we provide," said Prem Shah, PharmD, executive vice president, Chief Pharmacy Officer and President, Pharmacy and Consumer Wellness, CVS Health.

This new approach is scheduled to be launched with pharmacy benefit managers (PBMs) for commercial payors in 2025.

The company also reaffirmed its financial guidance for the year 2023. It continues to see adjusted EPS at $8.60 (up or down 10 cents) on revenue in the range of $351.5-357.3 billion.

The average analyst estimate is $8.60 for FY23 EPS on revenue of $353.7 billion.

"We are successfully executing on our strategy to advance the future of health care while unlocking new value for consumers," said CVS Health President and CEO Karen S. Lynch.

CVS Health has approved a quarterly dividend of $0.665 cents per share, marking a 10% increase from the previous dividend of $0.605 cents per share. The dividend will be payable on February 1, 2024, to shareholders of record as of January 22, 2023.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 4 months ago
Bridgewater Associates LP Acquires 212,648 Shares of CVS Health Co. (CVS)
By: MarketBeat | November 24, 2023

• Bridgewater Associates LP boosted its holdings in CVS Health Co. (NYSE:CVS) by 8.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,686,418 shares of the pharmacy operator's stock after buying an additional 212,648 shares during the period. CVS Health makes up about 1.1% of Bridgewater Associates LP's investment portfolio, making the stock its 17th biggest position. Bridgewater Associates LP owned approximately 0.21% of CVS Health worth $185,712,000 at the end of the most recent quarter...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 5 months ago
CVS Health Giant Prepares for Earnings Call
By: Schaeffer's Investment Research | October 31, 2023

• CVS Health is set post earnings before the market opens tomorrow

• CVS has a history of positive post-earnings moves

Pharmaceutical concern CVS Health Corp (NYSE:CVS) will enter the earnings confessional before the open tomorrow. The mean analyst earnings estimate is $2.13 per share, with revenue expected to rise to $88.25 billion year on year for the third quarter.

Looking back at CVS Health's last eight quarterly reports, the company's shares tend to move higher after earnings. Over the last two years, all but two post-earnings sessions finished positive. The security averaged a 4.4% swing, regardless of direction, the day after reporting results, and the options pits are pricing in a nearly 8.4% move this time around.

Ahead of the event, CVS Health stock was last seen 0.6% higher at $68.44, though it's struggled for most of the year on the charts, down 26.4% in 2023. A mid-August bear gap sent CVS to its lowest level since November 2020, just above the $64.50 mark. The equity pulled sharply back last week as well, though the $66 level stepped up to stymie the losses.



In the options pits, CVS sports 50-day put/call volume ratio of 1.17 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This ratio sits higher than 92% of all other readings from the past 12 months, suggesting a much healthier appetite for puts over the last 10 weeks.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 6 months ago
CVS Health Co. (CVS) Shares Acquired by C2C Wealth Management LLC
By: MarketBeat | September 30, 2023

• C2C Wealth Management LLC lifted its position in shares of CVS Health Co. (NYSE:CVS) by 46.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,769 shares of the pharmacy operator's stock after buying an additional 11,373 shares during the quarter. C2C Wealth Management LLC's holdings in CVS Health were worth $2,555,000 at the end of the most recent quarter...

Read Full Story »»»

DiscoverGold
👍️0
abrooklyn abrooklyn 6 months ago
CVS Health announces quarterly dividend

Source: PR Newswire (US)
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty and a half cents ($0.605 cents) per share on the Common Stock of the Corporation. The dividend is payable on November 1, 2023, to holders of record on October 20, 2023.

About CVS Health
CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. We support individuals with their health – whether that's managing health conditions, staying compliant with their medications or accessing affordable health services in the most convenient ways. Our goal is to create seamless connections across the health care system, simplifying the experience and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

CVS Health logo (PRNewsFoto/CVS Health)





Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-announces-quarterly-dividend-301935002.html

SOURCE CVS Health Corporation


Copyright 2023 PR Newswire
👍️0
DiscoverGold DiscoverGold 6 months ago
CVS Health Co. (CVS) Stake Lifted by Renaissance Technologies LLC
By: MarketBeat | September 9, 2023

• Renaissance Technologies LLC increased its stake in shares of CVS Health Co. (NYSE:CVS) by 97.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,069,953 shares of the pharmacy operator's stock after buying an additional 2,508,500 shares during the quarter. CVS Health comprises approximately 0.5% of Renaissance Technologies LLC's holdings, making the stock its 23rd largest position. Renaissance Technologies LLC owned 0.40% of CVS Health worth $376,748,000 at the end of the most recent reporting period...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 6 months ago
10 Most Oversold S&P 500 Stocks - $CVS $DLTR $C $JNJ make the list
By: Barchart | September 2, 2023

• 10 Most Oversold S&P 500 Stocks - $CVS $DLTR $C $JNJ make the list.



Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 7 months ago
$CVS Amazon's good news was bad news for this one. Tailed and recovered 66, that is the spot to hold now
By: Options Mike | August 20, 2023

• $CVS Amazon's good news was bad news for this one. Tailed and recovered 66, that is the spot to hold now.

Gap above if they shake this off.



Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 7 months ago
Blue Shield of California looks to cut reliance on CVS, taps Amazon
By: Investing.com | August 17, 2023

(Reuters) -Non-profit insurer Blue Shield of California plans to depend less on CVS Health (NYSE:CVS) as its pharmacy benefit manager and work with others such as Amazon.com (NASDAQ:AMZN) and Mark Cuban's drug firm to reduce reliance on companies that negotiate drug prices.

CVS shares slid over 6%, while rivals Cigna (NYSE:CI) Group and UnitedHealth Group (NYSE:UNH), which also have pharmacy benefit management units, fell 5% and 1%, respectively, in early trade.

Pharmacy benefit managers (PBMs), which maintain lists of drugs covered by health insurance plans and negotiate prices with manufacturers, have recently come under scrutiny from lawmakers for their role in rising healthcare costs.

Blue Shield, which has health plans that cover 4.8 million members, said it will now work with five different companies, including Mark Cuban Cost Plus Drug Company, to provide "convenient, transparent access to medications while lowering costs".

"Many in the industry will likely be watching this situation closely as managing the five partnerships could prove tricky , but if it (Blue Shield) is successful, we could see additional regionals move more in a similar direction," said Elizabeth Anderson, analyst at Evercore ISI.

Blue Shield will still retain CVS Caremark for its specialty pharmacy services, while Amazon will provide delivery of prescription medications as well as upfront pricing. Mark Cuban Cost Plus Drug Company will work to reduce surprise drug costs at the pharmacy pick-up counter.

"We look forward to providing care for Blue Shield of California's members who require complex, specialty medications – as we have for nearly two decades," CVS said in a statement.

Privately held Abarca will pay prescription drug claims, while smaller PBM Prime Therapeutics would work with Blue Shield to negotiate savings with drugmakers, the non-profit insurer said.

Blue Shield said it expects to save up to $500 million in annual drug costs once its multi-year strategy is fully implemented.

The loss of the Blue Shield pharmacy benefit management contract is another blow to Caremark, which is also set to lose the contract to manage Centene (NYSE:CNC)'s $40 billion annual pharmacy needs from next year.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 8 months ago
CVS Health lowers 2024 guidance despite second-quarter profit beat
By: Investing.com | August 2, 2023

CVS Health (NYSE:CVS) reported better-than-expected profit and revenue in the second quarter, but higher medical costs and a sweeping restructuring push led the healthcare giant to lower its 2024 earnings outlook and scrap its 2025 guidance.

Adjusted earnings per shares during the three months until the end of June slipped to $2.21 from $2.53 last year, but still beat consensus estimates of $2.13. Meanwhile, revenue rose 10.3% to $88.92 billion, topping forecasts of $86.41 billion.

"Our diversified business model delivered strong results this quarter," Chief Executive Officer Karen S. Lynch said in a statement. "We continue to execute on our strategy to expand access to health services across our care delivery channels and strengthen our engagement with consumers to improve their health and well-being."

According to Reuters, the Rhode Island-based pharmacy chain said that it would slash about 5,000 non-customer facing roles in order to control expenses following a string of acquisitions. CVS recently purchased home health care services firm Signify Health for $8B and primary care provider Oak Street Health for $10.6B in a bid to expand the scope of the business beyond health insurance and pharmacies.

The group booked a restructuring charge of $496 million that was linked to the layoffs and other impairments, Reuters added.

Meanwhile, CVS backed its 2023 adjusted earnings guidance of $8.50 to $8.70. However, it expects its medical benefit ratio -- a ratio of claims paid to premium collected -- to come in at the higher end of its outlook of 84.7%, plus or minus 50 basis points. The number, which is used by CVS to gauge the performance of its insurance unit, has come under scrutiny following a post-COVID surge in demand for elective surgeries that were delayed during the pandemic.

The company also cut its 2024 adjusted income outlook, citing the impact of both the strategic overhaul and the elevated medical expenses. Chief Financial Officer Shawn Guertin said in a conference call that the firm now sees profit next year at between $8.50 to $8.70 a share, down from the prior forecast of $9 per share. Its 2025 adjusted earnings per share guidance of $10 was also withdrawn.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 8 months ago
CVS Health (CVS) beats profit estimates, starts restructuring to cut costs
By: Investing.com | August 2, 2023

(Reuters) - CVS Health Corp reported better-than-expected second-quarter earnings on Wednesday, and said it had begun implementing a restructuring program to cut costs after a recent spree of acquisitions.

The company has been expanding beyond health insurance and pharmacies with its buyouts of primary-care provider Oak Street Health and home healthcare services firm Signify Health.

CVS Health (NYSE:CVS), which completed the acquisitions earlier this year, has flagged higher-than-expected transaction and integration costs related to the deals.

The company said it recorded $496 million in pre-tax charges related to a restructuring program it started during the quarter to rein in costs.

CVS, which has a large retail pharmacy chain, a health insurance business and a pharmacy benefit management (PBM) unit, has said it would pause acquisitions in the near term but may look at "additional opportunities" over a longer timeframe.

Excluding items, the company reported a profit of $2.21 per share, above analysts' average estimate of $2.11 per share, boosted by strength in its PBM unit, which negotiates drug prices with manufacturers.

Sales at CVS' health services segment, which contains its PBM unit, rose 7.6% to $46.22 billion in the reported quarter compared with a year earlier.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 8 months ago
Easterly Investment Partners LLC Raises Stock Position in CVS Health Co. (CVS)
By: MarketBeat | July 21, 2023

• Easterly Investment Partners LLC increased its stake in CVS Health Co. (NYSE:CVS) by 120.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 162,291 shares of the pharmacy operator's stock after purchasing an additional 88,568 shares during the quarter. Easterly Investment Partners LLC's holdings in CVS Health were worth $12,060,000 at the end of the most recent quarter...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 8 months ago
CVS Health Sees Unusually High Options Volume (CVS)
By: MarketBeat | July 19, 2023

• CVS Health Co. (NYSE:CVS) was the target of unusually large options trading activity on Wednesday. Investors acquired 197,703 call options on the company. This is an increase of approximately 407% compared to the average daily volume of 38,994 call options...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 9 months ago
CVS Health Co. (CVS) Receives Consensus Rating of "Moderate Buy" from Brokerages
By: MarketBeat | June 24, 2023

• Shares of CVS Health Co. (NYSE:CVS) have received an average rating of "Moderate Buy" from the sixteen brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $107.26...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 9 months ago
Keel Point LLC Acquires 9,921 Shares of CVS Health Co. (CVS)
By: MarketBeat | June 16, 2023

• Keel Point LLC grew its holdings in shares of CVS Health Co. (NYSE:CVS) by 26.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,499 shares of the pharmacy operator's stock after acquiring an additional 9,921 shares during the period. Keel Point LLC's holdings in CVS Health were worth $3,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC)...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 9 months ago
Is It Time To Bet On CVS?
By: Barchart | June 7, 2023

The June/July issue of Fortune is out. It is dedicated to its Fortune 500 rankings. One CEO who appears prominently in the magazine is CVS (CVS) CEO, Karen Lynch.

Not only does Lynch appear in an article lamenting that despite the number of female and Black CEOs in the Fortune 500, it's still an abysmal record. I couldn’t agree more.

However, that’s not why I’ve brought up Lynch’s name.

The reason I’m talking about Lynch is that she appears in a second article in Fortune’s latest issue discussing Big Healthcare and whether it will be able to fix what ails America’s healthcare system.

CVS stock is down 24% year-to-date and up just 7% over the past five years. While the article paints a positive picture of CVS’s contribution to fixing healthcare in America, the appearance in Fortune could be a curse rather than a blessing.

My big question is whether it’s time to bet on CVS.

The Upside For CVS

First of all, for all those like me who didn’t know this juicy factoid: Fortune points out that the company began life as the Consumer Value Store, hence the CVS acronym. I’m a business history freak, so that’s one to file away, but I digress.

Since Lynch became CEO in 2021, she’s made two mid-sized acquisitions: In September 2022; the company announced that it would acquire Signify Health for $8 billion. It completed its acquisition of the home healthcare provider in late March.

“This transaction advances our value-based care strategy by enhancing our presence in the home,” Lynch stated in CVS’s press release announcing the acquisition’s completion. “Our expanded capabilities will bring us closer to the consumer as we continue to redefine how people access and experience care that is more affordable, convenient and connected."
In February, CVS announced a second multi-billion-dollar acquisition, agreeing to pay $10.6 billion for Oak Street Health. This primary care provider operates storefront clinics in lower-income neighborhoods in 21 states.

“Combining Oak Street Health's platform with CVS Health's unmatched reach will create the premier value-based primary care solution,” Lynch said in February, announcing the deal. “Enhancing our value-based offerings is core to our strategy as we continue to redefine how people access and experience care that is more affordable, convenient and connected.”

The company’s transformation from a pharmacy chain to a pharmacy benefit manager to a primary care provider and, ultimately, to representing your entire healthcare ecosystem started years ago but is now accelerating under Lynch.

“While recognizing that we have shareholders, and a lot of different stakeholders, my personal passion is, ‘How do we improve the health care system?’?” Lynch told Fortune. “We have the opportunity to really drive engagement, simplicity, effectiveness—and to drive patients to the right care at the right time, in the right places.”

While there is no doubt that the stakes are high, if CVS can walk the fine line between altruistically helping patients and profiting handsomely from doing so, five to 10 years from now, those holding over the entire period will be greatly rewarded for their patience and loyalty in the plan.

That said, its stock has performed poorly in recent years precisely because investors doubt its long-term strategy.

The Big Downside to Its Vision

As Fortune points out, CVS is one of several large healthcare companies looking to transform the American healthcare system through value-based care, a panacea that might not come to fruition.

“In conversations with a couple dozen stakeholders, including three former CMS administrators, about Big Health Care’s fitness for the value-based care role, most opinions landed between skeptical and wait-and-see. Will care improve? Maybe, through better coordination. Will it lower costs? Unlikely. Is investment in primary care, whatever the source, a good thing? You bet,” Fortune contributors Maria Aspan and Erika Fry wrote.

So, if doctors, other health practitioners, and patients fail to buy into the value-based model pushed by companies like CVS, the expensive acquisitions Lynch and the company’s previous CEOs have made -- $130 billion since 2006 -- will have all been for nothing.

Let’s put it this way.

Before its acquisition spree began, CVS had $1.6 billion in long-term debt in 2005. That was 10.4% of its total assets. At the end of March, its long-term debt was $56.5 billion, or 23.6% of its total assets, more than double what it was less than 20 years ago.

Sure, its operating profits have grown from $2.0 billion in 2005 to $7.7 billion in 2022, a compound annual growth rate (CAGR) of 8.3%. However, the CAGR of its debt was nearly 23% over the same period.

With higher interest rates, this becomes a far more significant issue should the business model fail to gain the traction necessary to pay for all of this debt incurred.

Is It Time To Bet on CVS?

CVS has a trailing 12-month free cash flow of $17.4 billion. Based on an enterprise value of $145.4 billion, it has a free cash flow yield of 12%. I consider anything over 8% to be in value territory.

So, my answer would be yes, but only if you’re a patient investor. Lynch’s plan could take several years to play out.

I guess we’ll find out.

Read Full Story »»»

DiscoverGold
👍️0
Reyeton Reyeton 9 months ago
Our CEO on cover Fortune Magazine:

https://finance.yahoo.com/news/fortune-500-record-number-female-100000590.html
👍️0
DiscoverGold DiscoverGold 10 months ago
CVS Health already bakes in more than the worst-case scenario, TD Cowen 'would add here'
By: Investing.com | May 19, 2023

TD Cowen analysts reiterated an Outperform rating and $111 price target on CVS Health (NYSE:CVS) in a note Friday, telling investors that the current trough valuation "overly discounts" near-term risks.

"We would add here," said the analysts. "Concerns over a number of issues, including PBM transparency and 340B volumes among others, have driven shares down ~25% since Feb., which is much more than a worst-case EPS impact of 16% (lose all 340B vol. & 20% of PBM AOI), or $1.42 to our 2024 adjusted EPS estimate of $9.03."

CVS shares have fallen more than 24% in 2023 and over 25% in the last 12 months, trading above the $69 mark.

They said the shares, which are currently trading near 10-year trough multiples, already bake in more than the worst-case scenario from the headwinds.

"At current levels, we view shares as very attractive, given they do not reflect the likelihood of CVS returning to low double-digit/mid-teens adjusted EPS growth starting in 2025, and recommend adding here," they concluded.

Read Full Story »»»

DiscoverGold
👍️0
Reyeton Reyeton 10 months ago
Will this give our share price a boost?

https://finance.yahoo.com/news/virginia-community-health-centers-aetna-140000796.html
👍️0
DiscoverGold DiscoverGold 11 months ago
CVS Health to pause M&A and focus on integration
By: Investing.com | May 3, 2023

(Reuters) -CVS Health Corp said on Wednesday it would pause its recent acquisition spree as it focuses on integrating purchases of healthcare service provider Signify Health and primary care provider Oak Street Health.

CVS, which has a large retail pharmacy chain, and major health insurance and pharmacy benefit manager (PBM) units, like other healthcare rivals has been looking to broaden the services it offers.

CEO Karen Lynch said CVS will focus on integrating Signify and Oak Street with its other businesses in the near term.

Longer term, Lynch said, the company might look at additional opportunities in home or health services.

Rival Walgreens Boots Alliance (NASDAQ:WBA) in January also said it would not strike new deals in the short term after a spate of acquisitions in the healthcare space.

Major companies Amazon.com Inc (NASDAQ:AMZN) and Walgreens have expanded their healthcare business footprints, especially primary and urgent care, as they look to benefit from growth in the sector.

CVS cut its full-year profit forecast on Wednesday to account for transaction and integration costs related to the two deals, and its shares fell 3%.

The earlier-than-expected closing of the Oak Street deal on Tuesday is likely to result in increased interest costs for the year, analysts said. The deal was initially expected to close later this year.

CVS cut its 2023 adjusted earnings forecast to $8.50 to $8.70 per share from its prior view of $8.70 to $8.90.

Morningstar analyst Julie Utterback said investors might be disappointed that the company pushed down its profit forecast after completing the Oak Street acquisition this week.

Lynch said the early closure could weigh on CVS earnings in the short term, but would also enable the healthcare conglomerate to unlock cost cutting synergies earlier.

The company did beat Wall Street estimates for first-quarter profit and revenue on Wednesday, as a recovery in medical procedures boosted sales of prescription drugs.

CVS reported an adjusted profit of $2.20 per share for the first quarter, topping analysts' estimates by 11 cents, according to Refinitiv data.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 11 months ago
CVS Health reports 11% sales growth but cuts full-year earnings outlook as Oak Street deal closes
By: Morningstar | May 3, 2023

Revenues rise across all major business segments, even as regulatory pressures build on prescription-drug middlemen and Medicare Advantage

CVS Health (CVS) reported first-quarter earnings that beat analyst expectations Wednesday but cut its full-year guidance as it digests the acquisition of primary-care provider Oak Street Health.

The early close of the $10.6 billion deal for Oak Street, completed on Tuesday, "will be a short-term headwind" for 2023 earnings, CVS president and CEO Karen Lynch said on a conference call with analysts Wednesday. CVS cut its 2023 guidance for adjusted per-share earnings to a range of $8.50 to $8.70, down from $8.70 to $8.90.

Net income fell to $2.14 billion, or $1.65 per share, from $2.36 billion, or $1.77 per share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share fell to $2.20, from $2.30 a year earlier, but topped the FactSet consensus of $2.09. Revenue grew 11% to $85.28 billion, beating the FactSet consensus of $80.79 billion.

First-quarter revenues jumped in all three of CVS's major business segments, including healthcare benefits, health services, and pharmacy and consumer wellness.

The Oak Street acquisition comes on the heels of CVS's $7.8 billion acquisition of Signify Health, completed in March, boosting the company's presence in in-home services.

In the health services segment, which includes CVS's pharmacy benefit management business, revenues jumped 12.5% from a year earlier, to $44.59 billion, as the number of pharmacy claims processed increased 4% to 587 million. The results come as CVS, like other major players in the pharmacy benefit management business, faces growing scrutiny at the federal and state level. In Congress, lawmakers on both sides of the aisle have shown interest in reforming some PBM business practices, and executives from CVS and other major PBM players are slated to testify next week before the Senate Health, Education, Labor and Pensions Committee.

CVS has been targeted in some recent state-level actions against PBMs. The Minnesota Department of Commerce earlier this week fined CVS's Caremark PBM arm $500,000, alleging that the company steered patients to pharmacies or mail-order prescription services in which it had an ownership interest. And the Oklahoma Insurance Commission last month filed an administration action against CVS Caremark, alleging similar violations of state law.

CVS did not respond to a request for comment on the state actions. On the conference call Wednesday, Lynch addressed the scrutiny of PBMs generally, saying, "PBMs have consistently been found to operate in a highly efficient market and drive real savings to healthcare customers and members. Every day we deliver product choices for clients and members that help make care more affordable, accessible and simple."

Medicare Advantage is a key growth area for CVS but also faces regulatory pressures, as the federal government adjusts reimbursement rates and makes other tweaks that analysts expect may cut into industry growth. Heady Medicare Advantage growth rates seen in recent years "may decelerate and create some risk to the industry's 2024 growth prospects, in particular," Morningstar analyst Julie Utterback wrote in a recent research note.

"We have a long history of successfully working within Medicare Advantage funding levels to support program stability for our members," Lynch told analysts on the conference call Wednesday. CVS said it expects 12% membership growth in its Medicare Advantage business for the full year 2023. In late March, the City of New York awarded a Medicare Advantage contract for roughly 250,000 city retirees to CVS's Aetna unit--one of the largest client wins in Aetna's history, CVS said.

The end of the COVID-19 public health emergency next week will also make its mark on CVS, Lynch noted on the call Wednesday. The company's Medicaid business saw increased membership in the first quarter, Lynch said, but declines are expected for the rest of the year, after expiration of the public health emergency.

Pandemic-era legislation included a requirement that Medicaid programs keep people continuously enrolled for the duration of the public health emergency, but states can now resume redeterminations of eligibility, which may cause millions of people to lose health coverage, analysts say.

"As Medicaid members face potential disruption in their health benefits, we are using the full breadth of our portfolio of assets to help them avoid coverage losses and maintain positive health outcomes," Lynch said on the call.

In its retail business, CVS remains on track to close 300 stores this year and a cumulative total of 900 stores by 2024, Lynch said.

CVS shares are down 24% in the year to date, while the Health Care Select Sector SPDR ETF (XLV) is down 1.1% and the S&P 500 is up 7.7%.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 11 months ago
Don't Expect CVS Health (CVS) Stock to Sustain Latest Rally
By: Schaeffer's Investment Research | April 4, 2023

• CVS stock is fresh off a two-year low

• CVS has already shed more than 18% this year

CVS Health Corp (NYSE:CVS) stock is trading at $76.17 at last check, pacing for its fourth win in five sessions. CVS carries a hefty 18.2% year-to-date deficit, thanks to a long pullback that started in mid-February before culminating in a March 23, two-year low of $72.10. Despite a brief bounce from this floor, CVS could soon slip again, too, if past is precedent.



The stock's recent low comes amid historically low implied volatility (IV), which has been been a bearish combination before. Schaeffer's Quantitative Analyst Rocky White's data shows three similar signals in the last five years when CVS was trading within 2% of its 52-week low, while its Schaeffer's Volatility Index (SVI) ranked in the 20th percentile of its annual range or lower. This is currently the case with CVS Health stock's SVI of 20%, which ranks in the low 12th percentile of its annual range.

One month after these signals, the equity was lower 67% of the time to average a 4% dip. From its current perch, a move of comparable magnitude would push the shares back below $74.

Additional headwinds could come from a round of downgrades and/or price-target hikes, given 14 of the 18 firms in coverage calling CVS Health stock a "buy" or better. Plus, the 12-month consensus target price of $112.71 is a whopping 48% premium to its current perch.

At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), CVS carries a 50-day call/put volume ratio of 3.87 that sits higher than all but 4% of readings from the past year, suggesting a preference for bullish bets. Should this optimism start to unwind, shares could move lower still.

Read Full Story »»»

DiscoverGold
👍️0
Sanibel Island Sanibel Island 12 months ago
Millions about to loose Medicaid coverage as pandemic restrictions are lifted , google it for your own due deligence , most people are of color and Hispanic , will show in 2 nd quarter numbers
👍️0
DiscoverGold DiscoverGold 12 months ago
AHL Investment Management Inc. Increases Stock Holdings in CVS Health Co. (CVS)
By: MarketBeat | March 23, 2023

• AHL Investment Management Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS) by 6.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,846 shares of the pharmacy operator's stock after purchasing an additional 1,858 shares during the period. CVS Health comprises about 2.8% of AHL Investment Management Inc.'s portfolio, making the stock its 12th biggest position. AHL Investment Management Inc.'s holdings in CVS Health were worth $2,968,000 at the end of the most recent quarter...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 12 months ago
Ranking Top 7% (18 out of 250) of the Industry, I must say I am disappointed with it's performance last few months. I don't know of any negative news. I intent to hold the stock for long term.

DiscoverGold
👍️0
Lockman Lockman 12 months ago
What is going on with CVS?
👍️0
DiscoverGold DiscoverGold 12 months ago
CVS Health Co. (CVS) Shares Bought by Leith Wheeler Investment Counsel Ltd.
By: MarketBeat | March 19, 2023

• Leith Wheeler Investment Counsel Ltd. grew its stake in shares of CVS Health Co. (NYSE:) by 31.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,775 shares of the pharmacy operator's stock after acquiring an additional 10,040 shares during the period. Leith Wheeler Investment Counsel Ltd.'s holdings in CVS Health were worth $3,893,000 at the end of the most recent reporting period...

Read Full Story »»»

DiscoverGold
👍️0
Lockman Lockman 1 year ago
Think we'll see 70.00
👍️ 1
leftovers leftovers 1 year ago
CVS Health (NYSE:CVS) declares $0.605/share quarterly dividend, in line with previous.

Forward yield 3.18%

Payable May 1; for shareholders of record April 21; ex-div April 20.
👍️0
ming1234 ming1234 1 year ago
POS
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS Health confirms deal to buy Oak Street Health for $10.6 billion
By: Investing.com | February 8, 2023

CVS Health (NYSE:CVS) today confirmed it has reached an agreement to acquire Oak Street Health (NYSE:OSH) for $39 per share in cash, at an enterprise value of about $10.6 billion or an equity value of roughly $9.47B.

"Combining Oak Street Health's platform with CVS Health's unmatched reach will create the premier value-based primary care solution," said CVS Health President and CEO Karen Lynch. "Enhancing our value-based offerings is core to our strategy as we continue to redefine how people access and experience care that is more affordable, convenient, and connected."

The Wall Street Journal reported in recent days that the two companies are close to reaching an agreement. As a result, OSH stock soared about 30% from the start of the week before adding a further 5% in pre-open Wednesday.

"This agreement with CVS Health will accelerate our ability to deliver on our mission and continue improving health outcomes, lowering medical costs, and providing a better patient experience while offering significant value to our shareholders," said Oak Street Health CEO Mike Pykosz.

After the transaction closes, Oak Street Health will become part of CVS Health's recently formed Health Care Delivery organization.

Commenting on the WSJ report, Raymond James analysts said yesterday that the deal is about 5% dilutive at $39 a share.

“Suffice to say that CVS has acknowledged that it is behind its competitors, needs an asset it can scale and OSH is the best asset left… The key uncertainty is what changes CVS might make to OSH’s growth plans, and we note that WBA substantially raised Village MD’s co-located store openings,” they wrote.

CVS shares are up about 1.3% in premarket Wednesday on OSH news, as well as better-than-expected Q4 results.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS Health Corp earnings beat by $0.07, revenue topped estimates
By: Investing.com | February 8, 2023

CVS Health Corp (NYSE: CVS) reported fourth quarter EPS of $1.99, $0.07 better than the analyst estimate of $1.92. Revenue for the quarter came in at $83.85B versus the consensus estimate of $76.33B.

Guidance

CVS Health Corp sees FY 2023 EPS of $8.70-$8.90 versus the analyst consensus of $8.86.

CVS Health Corp's stock price closed at $85.98. It is down -11.86% in the last 3 months and down -17.95% in the last 12 months.

CVS Health Corp saw 5 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See CVS Health Corp's stock price’s past reactions to earnings here.

According to InvestingPro, CVS Health Corp's Financial Health score is "great performance".

Check out CVS Health Corp's recent earnings performance, and CVS Health Corp's financials here.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS nearing $10.5 billion deal for primary-care provider Oak Street Health - WSJ
By: Investing.com | February 6, 2023

(Reuters) - CVS Health Corp (NYSE:CVS) is close to an agreement to acquire primary care center operator Oak Street Health Inc for about $10.5 billion including debt, the Wall Street Journal reported on Monday, citing people familiar with the matter.

The companies are discussing a price of about $39 a share, the newspaper said.

The deal, if it goes through, could be announced as soon as this week, the report added.

CVS and Oak Street Health did not immediately respond to Reuters' requests for comment.

Bloomberg News reported last month that CVS was exploring a deal for Oak Street Health.

Oak Street Health runs primary care centers across the United States for recipients of Medicare, the U.S. government insurance program for Americans aged 65 and older, and has private equity firms such as General Atlantic and Newlight Partners among its shareholders.

CVS had also expressed interest in expanding into the primary care space, and was reportedly among the bidders to acquire primary care provider Cano Health before backing out.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
Earnings Preview: CVS Health Corp. (NYSE: CVS)
By: 24/7 Wall St. | February 6, 2023

• Here is a look at what analysts expect when the following three firms post their results first thing Wednesday morning.

CVS Health

The country’s third-largest provider of health care plans, CVS Health Corp. (NYSE: CVS) has seen its stock price rise dive by almost 21% in the past 12 months. Bloomberg reported last month that CVS is in discussions to acquire Oak Street Health’s brick-and-mortar centers for Medicare patients with low incomes and chronic health issues. New competition from Amazon for prescription drug sales may force CVS to protect its flank and put its diversification plans on hold. That competition is the primary reason for a drop of around 14% in CVS’s share price in just the past three months.

Analysts remain bullish on the stock, with 19 of 27 brokerages having a Buy or Strong Buy rating. The rest rate the shares at Hold. At a recent price of around $85.50 a share, the upside potential based on a median price target of $115.55 is about 35%. At the high price target of $130, the implied upside is 52%.

The consensus revenue estimate for the third quarter is $76.37 billion, which would be down 5.9% sequentially and by 0.3% year over year. Adjusted EPS are forecast at $1.93, down 10.1% sequentially and 2.5% lower year over year. For the full 2022 fiscal year, analysts are looking for EPS of $8.64, up 2.9%, and revenue of $314.7 billion, up about 7.7% year over year.
CVS stock trades at about 9.9 times expected 2022 EPS, 9.6 times estimated 2023 earnings of $8.86 and 8.9 times estimated 2024 earnings of $9.61 per share. The stock’s 52-week trading range is $84.82 to $111.25. CVS Health pays an annual dividend of $2.42 (yield of 2.82%). Total shareholder return for the past 12 months was negative 19.38%.

Read Full Story »»»

DiscoverGold
👍️0
Sanibel Island Sanibel Island 1 year ago
CVS shutting down Medavail Spot Rex pharmacies inside all Cano Health locations, first step for buyout of Cano Health. CVS did not walk away from negotiations they just stalled until buying Medavail to get them out of Cano Health buildings.
👍️0
Sanibel Island Sanibel Island 1 year ago
CVS made an excellent strategic move buying out MDVL Medavail, this removes all SpotRX locations out of Cano Health Care Centers and paves the way for CVS to buy CANO finally. Check press releases. Cano not talking yet , due your due deligence CVS on bought assets in Cano Health Centers and warehouse inventory and prescription information of customers. Great move CVS.
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS Health Co. (CVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
By: MarketBeat | January 25, 2023

• CVS Health Co. (NYSE:CVS) has been assigned a consensus rating of "Moderate Buy" from the eighteen analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $119.13...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS names new pharmacy services, consumer product chiefs
By: Investing.com | January 23, 2023

(Reuters) -CVS Health Corp said on Monday that David Joyner would return to head the U.S. diversified healthcare company's pharmacy services and tapped former Cigna Corp (NYSE:CI) executive Amy Bricker as its chief product officer for consumer business.

Joyner will become the chief of the pharmacy services segment, which also includes the company's pharmacy benefits management business Caremark, effective Jan. 30. He will succeed Alan Lotvin, who plans to retire in April, CVS said.

Bricker will start in the newly created role in February after serving as president of Express Scripts (NASDAQ:ESRX), rival Cigna Corp's pharmacy benefits unit.

The appointments follow some setbacks CVS faced in recent months in its businesses. Its largest health insurance plan for Medicare recipients received a lower performance rating from the U.S. Centers for Medicare and Medicaid Services in October. The lower rating could affect payments from the government for 2024, the company said.

In the same month, Centene (NYSE:CNC) Corp replaced Caremark with Express Scripts to manage the insurer's annual pharmacy spend of around $40 billion.

The loss of the account, along with the ratings decline, will likely reduce 2024 revenue by $2 billion, CVS said in November.

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS Health (CVS) PT Raised to $120.00
By: MarketBeat | January 14, 2023

• CVS Health (NYSE:CVS) had its target price boosted by Morgan Stanley from $119.00 to $120.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the pharmacy operator's stock. Morgan Stanley's target price would indicate a potential upside of 32.96% from the company's previous close...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
Assetmark Inc. Purchases 70,764 Shares of CVS Health Co. (CVS)
By: MarketBeat | January 14, 2023

• Assetmark Inc. raised its position in shares of CVS Health Co. (NYSE:CVS) by 4.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,722,035 shares of the pharmacy operator's stock after acquiring an additional 70,764 shares during the period. Assetmark Inc. owned approximately 0.13% of CVS Health worth $164,230,000 as of its most recent SEC filing...

Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS 1.66 Million Shares at $89.18 #darkpool prints
By: Money Flow Mel | January 12, 2023

• $CVS 1.66 million share #darkpool prints at $89.18.



Read Full Story »»»

DiscoverGold
👍️0
DiscoverGold DiscoverGold 1 year ago
CVS Opening shorter dated sweeper in to the 01/13 $91 CALLS
By: Money Flow Mel | January 6, 2023

• $CVS Opening shorter dated sweeper in to the 01/13 $91 CALLS

Presenting at the JPM Healthcare Conf on 01/10



Read Full Story »»»

DiscoverGold
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com